On September 30, 2026, the Federal Circuit denied Eli Lilly's petition for rehearing en banc in Teva Pharmaceuticals International GmbH v. Eli Lilly and Company, with Judge Dyk dissenting from the denial. The order leaves in place the April 2026 panel decision that reinstated a $177 million jury verdict on three Teva patents claiming methods of treating headache with humanized anti-CGRP antagonist antibodies.

Read more: https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2026/september/federal-circuit-denies-en-banc-rehearing-in-teva-v-eli-lilly-preserving-precedent-for-method-of-tr/